Figure 1 refers to Example 1 and presents a study of the local response in the salivary glands (Figure 1A) and in the stomach (Figure 1B) evaluated by ELISPOT by measuring the quantity of anti-urease IgA induced, expressed as spots/10<sup>6</sup> cells (Figure 1A) or as number of responding mice, exhibiting more than 2 IgA spots/mouse, (Figure 1B), after (a) administration of urease at D0 by the subcutaneous route (SC) in the left posterior sublumbar part ((a) and (c)) or in the neck ((b) and (d)), followed by a booster by the nasal route (N) and intragastric route (IG), at D28 ((a) and (b)) or at D28 and D56 ((c) and (d)).

Please replace the paragraph beginning at page 20, line 28 with the following rewritten paragraph.

Figure 2 refers to Example 1 and presents the levels of urease activity after a challenge, measured 4 hours after sacrificing mice which have received 3 times, on D0, D28, and D56, an inactivated bacterial preparation by the intragastric route ((a) and (c)) or subcutaneous route in the left posterior sublumbar part (b). In experiment (c), 10 µg of cholera toxin were added to the bacterial preparation. Experiments (d) and (e) correspond respectively to the positive and negative controls.

Please replace the paragraph beginning at page 21, line 18 with the following rewritten paragraph.

Figure 5 presents the quantities of serum immunoglobulins induced in monkeys subjected to the immunization procedures described in Example 2, and expressed as ELISA titre. A control group comprising 4 monkeys and three test groups are formed, each of the test groups comprising 8 monkeys; each test group is divided into two subgroups of 4 monkeys, one

B3

receiving only the inactivated *H. pylori* preparation (1, 2, and 3) and the other receiving the inactivated *H. pylori* preparation and recombinant urease (1u, 2u, and 3u). Group 1 and 1u correspond to the administration procedure: nasal + intragastric, 4 times; group 2 and 2u correspond to the administration procedure: intramuscular, 4 times; group 3 and 3u correspond to the administration procedure: nasal + intragastric, intramuscular, nasal + intragastric, intramuscular. The ELISA titre is measured three times: a first time at D0 (white band), a second time at D42 (shaded band), a third time at D78 (black band).

Please replace the paragraph beginning at page 22, line 2 with the following rewritten paragraph.

Figures 6A and 6B show the urease activity (Figure 6A) measured after 4 hours (OD<sub>550</sub> nm) using the Jatrox test (Procter & Gamble) and the bacterial load in mice infected with *H*.

pylori and then submitted to various treatments A-H (A: LT + urease, orally; B: QS-21 + urease, parenterally in the neck; C: QS-21 + urease, parenterally in the lumbar region; D: QS-21 alone, sub-cutaneously in the lumbar region; E: Bay R1005 + urease, parenterally in the neck; F: Bay R1005 + urease, parenterally in the lumbar region; G: Bay R1005 alone, sub-cutaneously in the lumbar region (control); H: saline, sub-cutaneously in the lumbar region (positive control)). I represents the negative control.